Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2017

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	For the Three Months Ended March 31,						For the Nine Months Ended March 31,
Medical Indication	2017			2016			2017			2016
Antibiotic	$	4,474		$	3,160		$	13,047		$	8,716
Anti Psychosis	14,433			1,061			47,119			4,533
Cardiovascular	14,815			16,652			39,484			38,059
Central Nervous System	11,124			14,264			32,028			20,351
Gallstone	11,157			14,698			37,465			53,389
Gastrointestinal	19,441			21,739			56,470			30,431
Glaucoma	4,868			6,006			15,962			19,371
Migraine	7,043			5,090			22,066			16,338
Muscle Relaxant	3,673			1,193			10,208			4,246
Obesity	1,024			1,023			2,819			2,853
Pain Management	6,085			7,178			20,132			23,386
Respiratory	4,256			5,308			9,426			6,703
Thyroid Deficiency	44,999			38,009			130,267			116,543
Urinary	2,619			6,506			12,413			10,148
Other	13,531			11,714			34,051			29,755
Contract manufacturing revenue	2,178			10,111			15,266			12,382
Net sales	165,720			163,712			498,223			397,204
Settlement agreement	(4,000		)	(23,598		)	(4,000		)	(23,598		)
Total net sales	$	161,720		$	140,114		$	494,223		$	373,606

Summary of products which accounted for at least 10% of total net sales

	For the Three Months Ended March 31,				For the Nine Months Ended March 31,
	2017		2016		2017		2016
Product 1	28	%	27	%	26	%	31	%
Product 2	7	%	10	%	8	%	14	%

Summary of customers which accounted for at least 10% of total net sales

	For the Three Months Ended March 31,				For the Nine Months Ended March 31,
	2017		2016		2017		2016
Customer A	27	%	25	%	28	%	28	%
Customer B	23	%	19	%	21	%	16	%